50 kilobecquerel (kBq) or 1.35 microcurie per kg body weight, IV, every 4 weeks
Duration of therapy: 6 doses
Comments: See manufacturer's product information for complete dosing instructions including decay correction factor table and calculation of correct volume for dosing.
Use: The treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease.
Renal Dose Adjustments
Mild to moderate renal impairment (CrCl 30 to 89 mL/min): No adjustment recommended
Severe renal impairment (CrCl less than 30 mL/min): Data not available
Liver Dose Adjustments
Mild hepatic impairment: No adjustment recommended
Moderate to severe hepatic impairment: Data not available
Precautions
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for dosing related precautions.
Dialysis
Data not available
Other Comments
Administration advice: Administer by slow intravenous injection over 1 minute.
Storage requirements: Store in the original container or equivalent radiation shielding.
Reconstitution/preparation techniques: The manufacturer's product information should be consulted.
General:
Follow procedures for proper handling and disposal of radioactive pharmaceuticals.
This preparation is approved for use only by persons under license by the Nuclear Regulatory Commission or the relevant regulatory authority of an Agreement State.
